|Bid||98.76 x 10000|
|Ask||102.75 x 10000|
|Day's range||101.55 - 104.90|
|52-week range||64.50 - 175.00|
|Beta (5Y monthly)||0.75|
|PE ratio (TTM)||N/A|
|Earnings date||22 Nov 2021 - 26 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||120.86|
SOUTH SAN FRANCISCO, Calif., October 20, 2021--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of its Exome 2.0, featuring the most comprehensive coverage of protein-coding and noncoding regions of the genome, as well as best-in-class performance to reduce downstream sequencing costs.
Holding on to stocks for the long term is hard. When stocks go down, many investors want to bail out. In this Motley Fool Live video recorded on Oct. 6, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss two stocks that you'll probably never want to sell.
SOUTH SAN FRANCISCO, Calif., October 13, 2021--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced an agreement with the Broad Institute for the distribution of a customized next-generation sequencing (NGS) target enrichment exome panel designed for the identification and research of a wide range of cancer, rare and inherited disease genes from patient samples. Twist wi